Expansion Opportunity Avinger is actively expanding beyond PAD to treat coronary artery disease with an image-guided CTO-crossing system, suggesting cross- or adjacent-market opportunities for invasive cardiology and interventional platforms.

Public Funding Signal Recent public offering and multiple financing rounds indicate strong investor interest and runway to scale commercialization, enabling growth initiatives and larger sales campaigns to hospital systems.

Product Line Leverage Current lumivascular devices include Lightbox, Ocelot, and Pantheris, with a recent limited release of Tigereye ST; this provides a ready-to-sell ecosystem for expanding selecting physicians and procurement discussions around imaging-guided atherectomy and CTO crossing.

Clinical Adoption Limited release at top U.S. clinical centers and focus on CTO crossing implies opportunities to partner with teaching hospitals, pilots, and key opinion leaders to accelerate adoption and expand reimbursement discussions.

SMB to Mid-Market Focus With a workforce in the 51-200 range and revenue in the lower enterprise bracket, there is potential to target regional hospitals and mid-market health systems with turnkey deployment, service, and training packages to accelerate deployment of lumivascular platforms.